Agreement of Medication Adherence and Pharmacotherapy Related Quality of Life as Assessed by Patients with Schizophrenia and Their Caregivers
Article Sidebar
Main Article Content
Abstract
Objective: To study agreement of medication adherence and pharmaceutical therapy-related quality of life as assessed by patients with schizophrenia and their caregivers, and to examine the relationship between medication adherence and pharmaceutical therapy-related quality of life. Method: This cross-sectional analytical study was conducted in 100 schizophrenic patients at Srithanya Hospital between January and June 2021. The study collected data from caregivers and patients, and medical records. The study assessed medication adherence with the Medication Taking Behavior in Thai Patients (MTB-Thai) questionnaire and assessed the pharmaceutical therapy-related quality of life with short version of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT). The study collected data twice: 1) the inpatient treatment period with the data collected from caregivers and 2) the outpatient treatment period with the data collected from patients and their caregivers. The inter-rater agreement was evaluated using the intraclass correlation (ICC) and the Bland-Altman methods. Their correlation was assessed using Pearson's correlation statistic. Results: Medication adherence scores as assessed by patients and caregivers showed a very good agreement in each dimension, with ICC ranging from 0.97 - 0.99. For the assessment with the short version of the PROMPT, good to very good agreement among raters was found in each dimension with ICC ranging between 0.85 - 0.95. Medication-taking forgetfulness dimension of medication adherence was positively correlated with obtaining medication and disease information (r = 0.23), satisfaction with drug efficacy (r = 0.35), and impacts of side-effects (r = 0.32). Discontinuation of the drug or self-initiated change of drug use were positively and significantly correlated with drug efficacy satisfaction (r = 0.30), impacts of side-effects (r = 0.25) and psychological effect of drug use (r = 0.35). Conclusion: The scores of the MTB-Thai and abbreviated version of the PROMPT as assessed by patients and their caregivers were in a good to very good agreement. A positive correlation was found between medication adherence and the following dimensions of pharmaceutical therapy-related quality of life--obtaining medication and disease information, satisfaction with the effectiveness of the drug, impacts from side effects of the drug and psychological effects of drug use
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
He H, Liu Q, Li N, Guo L, Gao F, Bai L, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the global burden of disease study 2017. Epidemiol Psychiatr Sci. 2020; 29: e91-e.
Patanon K, Manit S. The parameters for calculating the burden of schizophrenia in Thailand. J Ment Health Thai 2018; 26: 50-62.
Department of Mental Health. Mental health prevention information system [online]. 2013 [cited Jun 15, 2021]. Available from: mpis.srithanya.go.th/ MHC/PsyService.aspx.
Department of Mental Health. Reports of patients receiving psychiatric services [online]. 2020 [cited Aug 8, 2021]. Available from: www.dmh.go.th/report /datacenter/dmh/.
Department of Mental Health. Report on the number of patients admitted to departments under the department of mental health [online]. 2020 [cited Aug 8, 2021]. Available from: www.dmh.go.th/report /admit/
Department of mental health. Annual report [online]. 2020 [cited Oct 27, 2021]. Available from: www.dmh. go.th/report/pavgday/.
World Health Organization. Schizophrenia [online]. 2019 [cited Aug 9, 2020]. Available from: www.who. int/ news-room/fact-sheets/detail/schizophrenia.
Crismon L, Kattura RS, Buckley PF. Schizophrenia. In: Schwingham mer TL, DiPiro JT, editors. Pharmacotherapy hand book. 10th ed. NY: McGraw Hill; 2021.
Hasan A, Falkai P, Lehmann I, Gaebel W. Schizo phrenia. Dtsch Arztebl Int. 2020; 117: 412-19.
Simon GE, Stewart C, Yarborough BJ, Lynch F, Coleman KJ, Beck A, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry. 2018; 75: 254-60.
Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V, et al. A comprehen- sive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet 2019; 394: 1827 -35.
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychia tric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2020 ; 177: 868-72.
Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophre- nia. BMC Psychiatry. 2010; 10: 2.
Sukmak V, Thongkam J. Costs of inpatient care for schizophrenia at Khon Kaen Rajanagarindra Psy chiatric hospital. J Psychiatr Assoc Thailand 2013; 58: 421-32.
Wongsin U, Passakor S. Unit cost of schizophrenia, schizotypal and delusional disorders. Journal of Health Systems Research. 2019; 13: 420-17.
WHOQOL Group. Development of the world health organization WHOQOL-BREF quality of life assess ment. Psychol Med. 1998; 28: 551-8.
Mahatnirunkul S, Tuntipivatanaskul W, Pumpisan chai Wea. Comparison of the WHOQOL-100 and the WHOQOL-BREF (26 items). J Ment Health Thai. 1998; 1998: 4-15.
Colizzi M, Carra E, Fraietta S, Lally J, Quattrone D, Bonaccorso S, et al. Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res 2016; 170: 311-7.
Ahmad I, Khalily MT, Hallahan B. Reasons associated with treatment non-adherence in schizophrenia in a Pakistan cohort. Asian J Psychiatr 2017; 30: 39-43.
Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R, et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017; 4: 627-33.
Desalegn D, Girma S, Abdeta T. Quality of life and its association with current substance use, medica tion non-adherence and clinical factors of people with schizophrenia in Southwest Ethiopia: a hospital-based cross-sectional study. Health Qual Life Outcomes. 2020; 18: 82.
Vega D, Acosta FJ, Saavedra P. Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: a six-month naturalistic follow-up study. Compr Psychia try. 2021; 108: 152240.
Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020; 7: 749-61.
Sakthong P, Chinthammit C, Sukarnjanaset P, Sonsa-Ardjit N, Munpan W. Psychometric properties of the patient-reported outcomes measure of pharmaceutical therapy for quality of life (PROMPT-QOL). Value Health Reg Issues. 2017; 12: 41-9.
Sakthong P. Pharmacotherapy related quality of life in Thai patients with chronic diseases. Int J Clin Pharm. 2019; 41: 1004-11.
Sakthong P, Sonsa-Ardjit N, Sukarnjanaset P, Mun pan W, Suksanga P. Development and psychome tric testing of the medication taking behavior tool in Thai patients. Int J Clin Pharm. 2016; 38: 438-45.
Purba FD, Anggriani Y, Murtini T. EQ-5D-5L in Schizophrenia: differences between patients and nurses' reports. Health Qual Life Outcomes. 2021; 19: 240.
Becchi A, Rucci P, Placentino A, Neri G, de Girolamo G. Quality of life in patients with schizophrenia-comparison of self-report and proxy assessments. Soc Psychiatry Psychiatr Epidemiol. 2004; 39: 397-401.
Department of Mental Health. Manual of caring system for psychiatric patients at high risk of violence for institutions/hospitals under the Department of Mental Health [online]. 2020 [cited Oct 25, 2021]. Available from: www.mhso.dmh.go.th /fileupload/ 202010061612167390.pdf.
Albert R J, Mark S, William JW. Preferences of patients. In: James S, Cindy Y, editors. Clinical ethics: a practical approach to ethical decisions in clinical medicine. 8th ed. New York, NY: McGraw-Hill Education; 2015. p. 1.
Lynn Snow A, Cook KF, Lin PS, Morgan RO, Magaziner J. Proxies and other external raters: methodological considerations. Health Serv Res. 2005; 40: 1676-93.
Prochaska J, Velice W. The transtheoretical model of health behavior change. Am J Health Promot 1997; 12: 38-48.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. Br J Psychiatry. 2005; 187: 366-71.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016; 15: 155-63.
Akoglu H. User's guide to correlation coefficients. Turk J Emerg Med. 2018; 18: 91-3.
Vejoubon V. Effects of pharmaceutical care on glycemic control in type 2 diabetic elderly patients before and after hospital discharge [dissertation]. Bangkok: Chulalongkorn University; 2019.
Ralukruedej R. Assessment of pharmacotherapy-associated quality of life and medication taking behavior in psychiatric outpatients [dissertation]. Bangkok: Chulalongkorn University; 2019.
Kretchy IA, Appiah B, Agyabeng K, Kwarteng EM, Ganyaglo E, Aboagye GO. Psychotropic medicine beliefs, side effects and adherence in schizophrenia: a patient-caregiver dyad perspective. Int J Clin Pharm. 2021; 43: 1370-80.
Kaeokumbong CA. Effectiveness of pharmaceutical care at schizophrenia clinic in psychiatric hospital. Isan Journal of Pharmaceutical Sciences 2015; 11: 159-67.
Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH raise early treatment program. Am J Psychiatry. 2016; 173: 362-72.
Caqueo-Urízar A, Urzúa A, Mena-Chamorro P, Fond G, Boyer L. Adherence to antipsychotic medication and quality of life in Latin-American patients diagnosed with schizophrenia. Patient Prefer Adherence. 2020; 14: 1595-604.
